Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Esperion Therapeutics, Inc. (ESPR) SEC filings page provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Esperion is a commercial-stage biopharmaceutical company listed on the Nasdaq Stock Market LLC under the symbol ESPR, and its filings offer detailed insight into its cardiometabolic and rare/orphan disease business, including oral non-statin LDL-C therapies such as NEXLETOL and NEXLIZET.
Key filing types for Esperion include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, risk factors, financial statements, and discussion of operations. Current reports on Form 8-K and 8-K/A, several of which are referenced in the provided data, disclose material events such as financial results, underwritten public offerings of common stock, executive appointments, board changes, and other significant corporate developments.
Investors can also review notifications of late filing on Form 12b-25, which explain delays in periodic reports and provide management’s narrative regarding the status of financial closing procedures. For Esperion, these documents have included explanations related to quarterly financial close and corrections to previously furnished earnings releases.
On Stock Titan, Esperion’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the content of lengthy documents, highlight key sections, and surface items such as revenue drivers, commercialization plans for NEXLETOL and NEXLIZET, capital-raising transactions, and changes in executive leadership. Users can also identify trading symbol information, exchange listing details, and other disclosures related to Esperion’s common stock directly from these filings.
Esperion Therapeutics reported continued U.S. commercial momentum for its oral, non‑statin LDL‑C medicines as product sales rose to $40.3 million in Q2 2025 and $75.2 million for the six months ended June 30, 2025, up from $28.3 million and $53.1 million in the comparable 2024 periods, indicating stronger prescriptions and channel activity.
Collaboration revenue was approximately $42.1 million in Q2 2025 and $72.2 million year‑to‑date, down from $158.5 million for the prior six‑month period largely because prior‑year results included larger milestone recognition. Cash and cash equivalents declined to $86.1 million at June 30, 2025 from $144.8 million at December 31, 2024. Total assets were $347.1 million and total liabilities increased to $780.6 million, resulting in a stockholders' deficit of $(433.5) million.
The company recognized notable finance and capital transactions: proceeds from a $304.7 million sale of future DSE royalties are recorded as a royalty sale liability of approximately $295.9 million (net of issuance costs), and it maintains long‑term debt from a $150.0 million term loan with a carrying amount of $146.5 million. Interest expense increased year‑over‑year and contributed to a consolidated net loss of $53.18 million for the six months ended June 30, 2025. Esperion settled patent disputes with three ANDA filers who agreed not to market a generic version of NEXLETOL in the U.S. before April 19, 2040, while litigation against remaining ANDA filers continues.
Esperion Therapeutics, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 because it has not completed its quarter-end financial close. Management identified errors in an earnings release previously furnished and subsequently amended; the amended release contains preliminary, unaudited financial data based on management estimates that remain subject to completion of closing procedures. The Company requires additional time to finalize its condensed financial statements.
Esperion states it expects to file the Form 10-Q as soon as practicable and no later than the five-calendar-day extension permitted by Rule 12b-25. The filing notes that all other periodic reports for the last 12 months have been filed and that the Company does not anticipate a significant change in results versus the comparable prior-year period. Contact: Sheldon L. Koenig, President and CEO.
Esperion Therapeutics filed an Amendment No. 1 to its Form 8-K to correct its August 5, 2025 earnings release. The amendment corrects the Balance Sheet Data for the period ended June 30, 2025 and the Statement of Operations for the three and six months ended June 30, 2025, specifically net income (loss), net income (loss) per share, and income from operations for the three-month period. A corrected earnings release is furnished as Exhibit 99.1 dated August 11, 2025. Management states these figures are preliminary, unaudited, and subject to completion of the quarter-end close and may change; all other disclosures remain unchanged.
Esperion Therapeutics (ESPR) – Form 4 filing: On 07/01/2025 director John Craig Thompson received an option grant for 40,000 shares of common stock at an exercise price of $1.00 per share. The options vest in three equal annual installments beginning 07/01/2026 and expire on 07/01/2035. No common shares were bought or sold; the transaction is classified as an "A" (grant) and the beneficial ownership is reported as direct. Following the grant, Thompson beneficially owns 40,000 derivative securities (options) and no change was reported in non-derivative share ownership.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) has appointed Craig Thompson, MBA, a veteran biotechnology executive, to its Board of Directors effective July 1, 2025. Thompson will serve as an independent Class II director with a term running through the 2027 annual meeting. He will immediately join the Compliance, Nominating & Corporate Governance, and Commercial Committees.
Thompson brings more than two decades of commercial and C-suite experience to Esperion. He is currently CEO of Cerevance, LLC and holds board seats at NervGen Pharma. His prior leadership roles include CEO positions at Neurana, Anthera and senior commercial posts at Tetraphase, Trius, Pfizer and Merck, where he helped launch high-profile cardiovascular products such as Zocor and oversaw the global commercial development of torcetrapib/atorvastatin.
Under Esperion’s non-employee director compensation plan, Thompson will receive standard cash retainers and equity awards. The company has executed a customary indemnification agreement with him. No related-party transactions were disclosed.
A press release announcing the appointment was furnished as Exhibit 99.1 under Item 7.01; the disclosure is deemed “furnished” and not “filed” under the Exchange Act.
The Form 4 filed on 18 June 2025 shows that Esperion Therapeutics (ESPR) General Counsel Benjamin Looker sold 6,422 common shares on 17 June 2025 at an average price of $1.152 per share. A footnote clarifies the disposition was made solely to cover withholding taxes on recently vested RSUs, and the transaction was coded “S.” After the sale, Looker continues to hold 401,241 ESPR shares directly, meaning the divestiture equals roughly 1.6 % of his post-transaction stake. No derivative securities were exercised or disposed of.
Because the sale is small relative to the insider’s total ownership and is expressly tax-related, it is typically regarded as routine and low-impact for valuation or governance considerations. Nevertheless, investors tracking insider sentiment may note that the execution price signals the insider’s willingness to transact around the $1.15 level.
Form 4 highlights: Esperion Therapeutics (ESPR) President & CEO Sheldon L. Koenig reported the sale of 30,474 common shares on 06/17/2025 at an average price of $1.109 per share, transaction code “S”. Following the disposition, Koenig directly owns 1,541,488 ESPR shares.
The filing notes that the shares were sold solely to cover tax-withholding obligations incurred from the vesting of restricted stock units; the sale was not part of an open-market liquidation for personal gain. No derivative securities were acquired or disposed of, and no Rule 10b5-1 trading plan was indicated.
Because the sale represents roughly 2 % of Koenig’s direct holdings and leaves his ownership position largely intact, the transaction appears routine and is unlikely to materially affect investor perceptions of insider alignment or corporate governance.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
